DRKS00005311已完成1 期
A prospective, multi-center, single arm study – Evaluation of the safety and feasibility of MRI-guided transurethral ultrasound therapy for the ablation of prostate tissue in patients with localized prostate cancer - TULSA
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- N/a: Single Arm Study
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 65 Years 至 one（—）
- 性别
- Male
入选标准
- •1.Male, age = 65 years
- •2.Patient with low-risk, early-stage organ-confined prostate cancer (Clinical stage T1c or T2a, N0, M0).
- •3.Gleason score 6 (3+3) or max 7 (3+4)
- •4.PSA = 10 ng/ml
- •5.Eligible for MR imaging (DOC-10252)
- •6.Meets the following criteria on pre-treatment transrectal ultrasound imaging:
- •No cysts or calcifications > 1.0 cm in size
- •No evidence of extraprostatic extension or seminal vesicle invasion
- •Overall prostate size less than 5 cm in sagittal length and less than 6 cm in diameter
- •7.Biopsy confirmed adenocarcinoma of the prostate: performed at least 6 weeks prior to and preferably no more than 6 months prior to the scheduled treatment, or at the discretion of the PI.
- •8.Eligible for General Anesthesia, as defined in American Society of Anesthesiologists (ASA)
- •9.Normal rectal anatomy and rectal mucosa on digital rectal examination
排除标准
- •1.Bleeding disorder (International Normalized Ratio (INR) > ULN and partial thromboplastin time (PTT) > ULN)
- •2.Abnormal coagulation and current anticoagulant therapy. (Patients whose anticoagulation therapy can be temporarily reversed within 7 days prior to treatment delivery are eligible.)
- •3.Acute or chronic Urinary Tract Infection (UTI)
- •4.Interest in future fertility
- •5.History of allergy to latex and any relevant medication
- •6.History of any other malignancy other than skin cancer within the previous 5 years. Patients that have had a previous malignancy and no recurrence of that malignancy within the past 5 years will be allowed.
- •7.Patients with peripheral arterial disease with intermittent claudication or Leriches Syndrome (i.e. claudication of the buttocks or perineum)
- •8.Prior treatment of the prostate gland, including but not limited to radiation therapy (external beam or brachytherapy), high intensity focused ultrasound, thermal therapy, androgen deprivation therapy, bilateral orchiectomy, transurethral needle ablation of the prostate and transurethral resection of the prostate.
- •9.Prior treatment with 5 alpha reductase inhibitor allowed provided it was for benign prostatic hypertrophy (not as prostate cancer treatment or prevention) and as long as drug has been stopped for approximately 6 months and if less, clinical justification must be provided.
- •10.History of any major rectal or pelvic surgery
- •11.History of ulcerative colitis or other chronic inflammatory conditions affecting rectum (includes rectal fistula, anal stenosis, hemorrhoids)
- •12.History of documented clinical prostatitis requiring therapy within previous 6 months
- •13.History of urethral and bladder outlet disorders, including urethral stricture disease, urethral diverticulae, bladder neck contracture, urethral fistulae which had required prior urethrotomy, urethral stenting, urethroplasty or chronic indwelling urethral catheter
- •14.Patients with artificial urinary sphincter or any penile implant (metallic or non-metallic)
- •15.Neurologic bladder disorders
- •16.Untreated bladder stones
- •17.History of acute urinary retention
- •18.Confirmed or suspected bladder cancer
- •19.Urinary sphincter abnormalities
- •20.Active untreated gross hematuria for any cause
- •21.Post Void Residual (PVR) bladder volume > 250 mL
- •22.Obstructing median lobe enlarged out of proportion to the rest of the prostate and protruding significantly into the bladder, sometimes referred to as ball valve” median lobe.
- •23.Received any prostate related investigational treatment within 12 months of Visit 1
- •24.Undergone major surgery/surgical therapy unrelated to prostate and adjacent organs must have sufficient healing period (discretion of the investigator) prior to the Baseline visit
- •25.Prior pelvic radiotherapy
- •26.Any of the following within the 6 months prior to Visit 1: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure (NYHA Class III or IV), cerebrovascular accident, transient ischemic attack, pulmonary embolism, sustained ventricular tachycardia, clinically significant bradycardia, ventricular fibrillation, or advanced heart block
- •27.Ongoing cardiac dysrhythmias = grade II (NCI CTCAE v4.0)
- •28.History of Parkinson’s disease or multiple sclerosis
- •29.History of alcohol or drug abuse
- •30.Treatment with antidepressant drugs which in the judgment of the investigator would make the patient inappropriate for entry i
研究者
相似试验
已完成
不适用
A pRospective, multicenter, single-arm study EvaLuating the safety and feasIbility of Targeted Lung Denervation (TLD) for the trEatment of severe asthma.Asthmalung disease10038716NL-OMON45521VAIRA, Inc10
尚未招募
4 期
The aim is to evaluate the safety and efficacy of MeRes100™ Sirolimus Eluting BioResorbable Vascular Scaffold in coronary artery disease patients.It enhances coronary luminal diameter in symptomatic ischemic heart disease, addressing de novo lesions in native coronary arteries.CTRI/2024/02/062438Meril Diagnostics Private Limited
招募中
4 期
A study to assess result after shoulder surgeryCTRI/2023/04/052027Healthium Medtech Limited
进行中（未招募）
4 期
A study to assess result after knee surgeryCTRI/2023/04/051727Healthium Medtech Limited
招募中
4 期
A study to assess result after shoulder surgeryCTRI/2023/07/055473Healthium Medtech Limited